Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of Adding Venetoclax to a Reduced Intensity Conditioning Regimen and to Maintenance in Combination With a Hypomethylating Agent After Allogeneic Hematopoietic Cell Transplantation for Patients With High Risk AML, MDS, and MDS/MPN Overlap Syndromes

NCT03613532 is registered in ClinicalTrials.gov with Jacqueline Garcia, MD as lead sponsor.

NCT NCT03613532
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03613532 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of Adding Venetoclax to a Reduced Intensity Conditioning Regimen and to Maintenance in Combination With a Hypomethylating Agent After Allogeneic Hematopoietic Cell Transplantation for Patients With High Risk AML, MDS, and MDS/MPN Overlap Syndromes
Lead sponsor
Jacqueline Garcia, MD
Phase
Phase 1
Overall status
Active, not recruiting
Start date
October 24, 2018
Completion date
March 5, 2030
Enrollment
102 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia (aml), chronic myelomonocytic leukemia (cmml), hematopoietic stem cell transplant, mds/myeloproliferative neoplasm-unclassifiable (mds/mpn-unclassifiable), myelodysplastic syndrome (mds)